Financial Performance - The company's operating revenue for Q1 2025 was CNY 104,965,754.87, representing a 12.97% increase compared to CNY 92,913,492.03 in the same period last year[4]. - Net profit attributable to shareholders was CNY 6,313,627.91, up 20.04% from CNY 5,259,774.40 year-on-year[4]. - The net profit after deducting non-recurring gains and losses surged by 183.29%, reaching CNY 3,568,906.31 compared to CNY 1,259,788.90 in the previous year[4]. - Operating profit for Q1 2025 was ¥7,339,544.60, representing a 37.4% increase from ¥5,339,694.66 in Q1 2024[17]. - The company reported a net profit of RMB 4,183,507.50 for the period, recovering from a loss of RMB 2,130,120.41 in the previous period[14]. - The company’s total comprehensive income for Q1 2025 was ¥6,313,386.40, compared to ¥5,250,995.52 in Q1 2024[18]. Cash Flow and Assets - The net cash flow from operating activities was CNY 33,623,356.39, a significant recovery from a negative cash flow of CNY -13,797,072.47 in the same period last year[4]. - Cash flow from operating activities for Q1 2025 was ¥33,623,356.39, a significant recovery from a negative cash flow of -¥13,797,072.47 in Q1 2024[20]. - Cash and cash equivalents at the end of Q1 2025 totaled ¥223,563,268.29, down from ¥249,365,094.31 at the end of Q1 2024[21]. - The company's cash and cash equivalents increased to RMB 223,974,465.68 from RMB 182,005,082.42, representing a growth of approximately 23%[12]. - Total assets at the end of the reporting period were CNY 2,010,050,555.33, a decrease of 0.77% from CNY 2,025,574,271.48 at the end of the previous year[5]. - As of March 31, 2025, the company's total assets amounted to RMB 2,010,050,555.33, a decrease from RMB 2,025,574,271.48 as of December 31, 2024[12]. Liabilities and Equity - The total current liabilities decreased to RMB 99,591,869.86 from RMB 122,680,316.13, a reduction of about 19%[14]. - The company's total equity attributable to shareholders rose to RMB 1,907,785,955.18 from RMB 1,900,547,548.83, indicating a slight increase[14]. Research and Development - R&D investment totaled CNY 19,366,231.25, accounting for 18.45% of operating revenue, down from 22.86% in the previous year[5]. - Research and development expenses for Q1 2025 were ¥19,366,231.25, a decrease of 8.2% from ¥21,237,594.64 in Q1 2024[17]. Shareholder Information - The company had a total of 8,533 common shareholders at the end of the reporting period[8]. - Favored Tech Corporation Limited held 62.16% of the shares, with a total of 208,533,334 shares[9]. - The company repurchased a total of 4,658,312 shares, accounting for 1.3886% of the total share capital, with a total expenditure of RMB 50,202,577.62[11]. Non-Recurring Gains - The company reported non-recurring gains of CNY 2,744,721.60 after tax, primarily from government subsidies and other non-operating income[6].

Financial Performance - The company's operating revenue for Q1 2025 was ¥636,072,724.12, representing a 6.40% increase compared to ¥597,800,414.49 in the same period last year[4] - Net profit attributable to shareholders decreased by 53.27% to ¥27,325,457.18 from ¥58,475,460.53 year-on-year[4] - The net profit after deducting non-recurring gains and losses fell by 43.03% to ¥23,922,715.50 from ¥41,989,077.29 in the previous year[4] - The basic earnings per share decreased by 54.05% to ¥0.17 from ¥0.37 in the same period last year[5] - Net profit for Q1 2025 was ¥26,088,743.75, a decrease of 55.2% from ¥58,299,386.78 in Q1 2024[18] - Basic earnings per share for Q1 2025 was ¥0.17, down from ¥0.37 in Q1 2024[18] - The company reported a decrease in other income from ¥20,842,296.57 in Q1 2024 to ¥5,209,381.77 in Q1 2025[17] Cash Flow and Liquidity - The company reported a net cash flow from operating activities of -¥77,627,967.80, compared to ¥99,771,166.88 in the same period last year, indicating a significant cash outflow[4] - Cash flow from operating activities in Q1 2025 was negative at -¥77,627,967.80, compared to positive cash flow of ¥99,771,166.88 in Q1 2024[21] - Cash and cash equivalents at the end of Q1 2025 totaled ¥393,820,716.03, down from ¥509,359,744.07 at the end of Q1 2024[22] - Investment activities generated a net cash outflow of -¥56,443,868.61 in Q1 2025, compared to -¥80,481,716.28 in Q1 2024[22] - Financing activities resulted in a net cash outflow of -¥7,298,092.03 in Q1 2025, contrasting with a net inflow of ¥27,639,882.07 in Q1 2024[22] Assets and Liabilities - The total assets at the end of the reporting period were ¥3,212,196,958.83, a decrease of 3.54% from ¥3,330,238,800.71 at the end of the previous year[5] - Current assets totaled CNY 1,891,580,660.40, down from CNY 2,044,547,714.82, indicating a decrease of about 7.47%[14] - Cash and cash equivalents decreased to CNY 393,820,716.03 from CNY 531,710,588.83, representing a decline of approximately 26.0%[14] - Accounts receivable decreased to CNY 751,058,867.62 from CNY 832,608,794.06, a reduction of about 9.8%[14] - Inventory slightly decreased to CNY 400,397,523.65 from CNY 413,900,391.22, showing a decline of approximately 3.3%[14] - Total liabilities decreased to CNY 1,575,508,777.87 from CNY 1,730,072,262.46, reflecting a decrease of about 8.95%[16] - Total equity increased to CNY 1,636,688,180.96 from CNY 1,600,166,538.25, indicating an increase of approximately 2.27%[16] - The company reported a significant reduction in accounts payable, which decreased to CNY 347,449,529.83 from CNY 453,022,358.72, a decline of about 23.3%[15] - Long-term investments increased to CNY 11,490,420.67 from CNY 8,741,746.82, representing an increase of approximately 31.9%[14] Research and Development - Research and development expenses totaled ¥45,164,543.12, an increase of 12.10% from ¥40,290,049.56, with R&D expenses accounting for 7.10% of operating revenue, up from 6.74%[5] - The company experienced a significant increase in research and development expenses, which rose to ¥45,164,543.12 in Q1 2025 from ¥40,290,049.56 in Q1 2024[17] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 7,071[10] - The company has not reported any significant changes in shareholder relationships or participation in margin trading activities[11] Accounting Standards - The new accounting standards or interpretations will be implemented starting from 2025, affecting the financial statements from the beginning of that year[23]

Financial Performance - The company's operating revenue for 2024 was approximately ¥11.68 billion, a decrease of 28.94% compared to ¥16.44 billion in 2023[21]. - The net profit attributable to shareholders for 2024 was a loss of approximately ¥332 million, significantly improved from a loss of ¥1.87 billion in 2023[21]. - The basic earnings per share for 2024 was -¥0.27, an improvement of 82.35% from -¥1.53 in 2023[22]. - The weighted average return on equity increased by 13.85 percentage points to -2.96% in 2024 from -16.81% in 2023[22]. - The net cash flow from operating activities increased by 36.86% to approximately ¥908.77 million in 2024, driven by improved management of accounts receivable and inventory[23]. - The total assets decreased by 11.67% to approximately ¥26.63 billion in 2024 from ¥30.14 billion in 2023[21]. - The company achieved operating revenue of CNY 1,168,046,860.74, a year-on-year decrease of 28.94%, with main business revenue at CNY 1,133,926,430.00, down 26.51%[84]. - The net profit attributable to shareholders was a loss of CNY 33,205,940.00, although this represented a significant narrowing of losses compared to the previous year[84]. - The total assets at the end of the reporting period amounted to CNY 2,662,719,260.00, with a debt-to-asset ratio of 62.78%[84]. Research and Development - Research and development expenses accounted for 4.98% of operating revenue in 2024, up from 4.56% in 2023[22]. - The total R&D investment for the year was approximately ¥581.86 million, a decrease of 22.34% compared to the previous year, with R&D expenses accounting for 4.98% of revenue[60]. - The company applied for 238 new patents this year, with 138 granted, bringing the total to 725 applications and 433 granted patents[58]. - The company is developing a new type of cathode and anode material for high-energy density and high-rate cells, with a total investment of ¥25 million, and has invested ¥8.84 million this period[62]. - The company is advancing the second generation of semi-solid batteries (330Wh/kg) expected to be mass-produced by 2025, and the third generation (400Wh/kg) is under development with enhanced safety and stability features[33]. Market Position and Strategy - The company focused on optimizing its customer structure and shifting strategic emphasis towards overseas clients, resulting in a slight decline in product sales[23]. - Over half of the company's revenue comes from overseas clients, with significant partnerships established with companies like Mercedes-Benz and Mahindra Group, positioning the company among the top three in China's power battery export volume for 2024[37]. - The company is expanding its overseas production capacity in response to the growing global demand for electric vehicles, driven by carbon neutrality initiatives[48]. - The company aims to become a leader in global power battery technology, focusing on green travel, smart energy storage, and emerging business lines[130]. - The sales strategy emphasizes targeting automotive, overseas, and emerging markets, leveraging the SPS product as a benchmark to capture market share[132]. Corporate Governance and Compliance - The company has not disclosed any special arrangements for corporate governance[8]. - The company has received a standard unqualified audit report from its accounting firm[4]. - The company has not been subject to penalties from securities regulatory agencies in the past three years[162]. - The internal control system is effective, providing reasonable assurance for the authenticity and fairness of financial reporting, with no significant defects reported during the period[188]. - The company is committed to maintaining a robust corporate governance structure, ensuring compliance with relevant laws and regulations to protect investor rights[144]. Environmental and Social Responsibility - The company invested 2.637 million yuan in environmental protection during the reporting period[196]. - The company has not faced any administrative penalties for environmental issues during the reporting period[198]. - The company has completed annual carbon verification and improved the use of renewable energy through a combination of self-built distributed energy systems and purchased green electricity[200]. - The company has achieved industry-leading levels in battery material recycling technology, with multiple core patents authorized in China and the U.S.[193]. Human Resources and Talent Management - The total remuneration for all directors, supervisors, and senior management at the end of the reporting period amounted to CNY 15,108,450.56[160]. - The company has implemented a comprehensive talent development system, focusing on management and professional skills enhancement through various training programs[175]. - The company maintains a competitive compensation system to attract and retain talent, with ongoing adjustments to the salary management policy[174]. - The total number of shares held by the chairman, Wang Yu, increased from 63 to 420.31 thousand shares, with a total pre-tax remuneration of 420.31 million yuan[148]. - The company has established a performance management scheme for senior management, linking their compensation to long-term development and shareholder interests[187].

Financial Performance - The company's operating revenue for Q1 2025 was CNY 49,945,726.11, representing a year-on-year increase of 0.65% compared to CNY 49,621,810.11 in the same period last year[4]. - Net profit attributable to shareholders was CNY 2,887,334.97, a significant increase of 454.20% from CNY 520,987.59 in the previous year[4]. - Basic and diluted earnings per share were both CNY 0.0190, reflecting an increase of 458.82% from CNY 0.0034 in the previous year[4]. - Operating profit for Q1 2025 reached CNY 4,354,118.45, significantly up from CNY 1,421,358.73 in Q1 2024, marking an increase of 206.4%[16]. - Net profit for Q1 2025 was CNY 2,887,334.97, compared to CNY 520,987.59 in Q1 2024, representing a growth of 453.5%[16]. - Total revenue for Q1 2025 was CNY 49,945,726.11, a slight increase of 0.65% compared to CNY 49,621,810.11 in Q1 2024[15]. Cash Flow and Assets - The net cash flow from operating activities was CNY 14,715,924.28, a turnaround from a negative cash flow of CNY -674,599.06 in the same period last year[4]. - Cash flow from operating activities for Q1 2025 was CNY 14,715,924.28, a turnaround from a negative cash flow of CNY -674,599.06 in Q1 2024[18]. - Total cash and cash equivalents at the end of Q1 2025 were CNY 94,276,564.79, compared to CNY 60,240,956.38 at the end of Q1 2024[18]. - The company's cash and cash equivalents decreased to RMB 115,444,805.63 from RMB 125,447,348.68, representing a decline of about 8.0%[12]. - The company's total assets at the end of the reporting period were CNY 906,843,675.98, a decrease of 0.42% from CNY 910,667,585.80 at the end of the previous year[5]. Liabilities and Equity - Total liabilities decreased to RMB 416,188,294.81 from RMB 422,899,539.60, a reduction of about 1.8%[14]. - The equity attributable to shareholders increased to RMB 490,655,381.17 from RMB 487,768,046.20, reflecting a growth of approximately 0.4%[14]. - The company reported a significant increase in contract liabilities to RMB 221,419,907.99 from RMB 198,761,272.97, representing a rise of about 11.4%[13]. Research and Development - Research and development expenses totaled CNY 4,457,299.38, down 22.53% from CNY 5,753,424.44 in the same period last year[4]. - The proportion of R&D expenses to operating revenue decreased to 8.92%, down 2.67 percentage points from 11.59% in the previous year[5]. - Research and development expenses for Q1 2025 were CNY 4,457,299.38, down from CNY 5,753,424.44 in Q1 2024, indicating a decrease of 22.5%[15]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 4,378, with the top ten shareholders' holdings detailed in the report[10]. - The number of shares held by the largest shareholder, Shen Wanzhong, is 48,482,000, accounting for 31.91% of total shares[11]. - The company has no significant changes in the participation of major shareholders in margin financing and securities lending activities compared to the previous period[12]. Other Income and Expenses - The company reported non-recurring gains of CNY 65,624.16, primarily from government subsidies and asset disposals[6]. - The company reported a significant increase in other income, which rose to CNY 88,184.56 in Q1 2025 from CNY 7,742,069.66 in Q1 2024[16]. - The company incurred credit impairment losses of CNY 6,781,219.65 in Q1 2025, compared to CNY 5,214,749.42 in Q1 2024, reflecting an increase of 30.1%[16].

Company Recognition and Achievements - In 2024, the company was recognized as a leading enterprise in high-quality development in the Chinese pharmaceutical industry, with its product, Dengzhanhua Jiangong, awarded as a top brand[5]. - The company ranked 89th in the 2023 Top 100 Chinese Traditional Medicine Enterprises list[6]. - The company's product, Dengzhanhua Xixin, was included in the "Green Yunnan Products" brand directory in September 2024[9]. - The company was listed among the top 100 manufacturing enterprises in Yunnan in 2024[10]. Financial Performance - The company's operating revenue for 2024 was ¥516,232,107.07, a decrease of 17.05% compared to ¥622,338,700.67 in 2023[32]. - The net profit attributable to shareholders for 2024 was -¥74,400,964.91, representing a decline of 509.83% from -¥12,200,282.05 in 2023[32]. - The gross profit margin decreased to 72.89% in 2024 from 80.94% in 2023[32]. - Total assets at the end of 2024 were ¥1,145,047,375.03, down 7.34% from ¥1,235,702,221.84 at the end of 2023[34]. - The total liabilities decreased by 6.88% to ¥219,970,089.73 in 2024 from ¥236,223,971.63 in 2023[34]. - The net assets attributable to shareholders decreased to ¥925,077,285.30 in 2024, a reduction of 7.44% from ¥999,478,250.21 in 2023[34]. - The cash flow from operating activities for 2024 was ¥39,967,466.89, a significant decrease of 65.15% compared to ¥114,686,505.28 in 2023[34]. - The basic earnings per share for 2024 was -¥0.60, a decline of 500.00% from -¥0.10 in 2023[32]. Operational Developments - In August 2024, the company established a wholly-owned subsidiary in Shanghai to enhance its comprehensive value and sustainable development[8]. - The company relocated its registered address to Yunnan Province in February 2024[7]. - The company completed the cancellation of 3,999,993 shares, reducing the total shares from 128,000,000 to 124,000,007[26]. - The company has 7 products in the Dengzhanhua series, with Dengzhan Shengmai capsules and Dengzhan Xixin injection being the main patented products[42]. Research and Development - The company is focusing on establishing high-level R&D collaborations with prestigious medical institutions to drive innovation and improve patient care[51]. - The company aims to improve product clinical value and market competitiveness through ongoing R&D projects[100]. - The company has established collaborations with hospitals for RCT studies, enhancing its research capabilities and product validation[101]. - The company holds a total of 48 patents, all of which are invention patents, indicating a strong focus on innovation[98]. Market Strategy and Expansion - The company plans to expand its market presence by exploring new markets along the "Belt and Road" initiative and enhancing digital marketing strategies[48]. - The company aims to achieve double growth in operating income and profit by optimizing resource allocation and enhancing operational efficiency in response to the complex market environment[59]. - The company aims to strengthen the entire industrial chain of the medicinal plant, Dan Zhan Hua, to ensure raw material availability and promote high-quality development[121]. - The company plans to enhance market share of its core products, Dan Zhan Sheng Mai capsules and Dan Zhan Xi Xin injections, by expanding into untapped markets and improving coverage in grassroots medical institutions[122]. Legal and Compliance Issues - The company is actively addressing issues related to fund occupation, ensuring legal rights are protected, and is in the process of pursuing legal actions against former controlling shareholders for the return of misappropriated funds[54][55]. - The company has ongoing litigation with a total claim amount of 273,107,940.57 yuan, with the first instance ruling against the company[146]. - The company has taken measures to recover the remaining occupied funds of 257 million yuan and corresponding returns[160]. - The company has initiated legal proceedings against Jinsha River and related parties, with the first instance court ruling against the company[148]. Environmental and Social Responsibility - The company is committed to environmental responsibility, ensuring compliance with pollution discharge standards and passing external inspections[50]. - The company has promoted the planting area of Dengzhanhua in Yunnan Province to over 3,000 mu, contributing to poverty alleviation and rural revitalization[108]. - The company sponsored 20,000 yuan for the "2024 Mile Women's Half Marathon" to support local cultural and sports development[108]. - The company adheres to environmental protection regulations and has implemented measures to ensure wastewater discharge is below permitted levels[110]. Challenges and Risks - The company is facing risks of core technical personnel loss during the relocation of its production base from Kunming to Mile, which may impact long-term development[135]. - The price of traditional Chinese medicine materials has significantly increased due to various factors, which will affect the production costs of related products[136]. - The company has accumulated a bad debt provision of 195.32 million yuan due to unreturned funds, with credit impairment losses increasing by 45.63% year-on-year[148]. - The company has faced significant cash flow and operational impacts due to the large amount of funds occupied by the defendants[148]. Corporate Governance - The company has a total of 9 board members, 3 supervisors, and 2 senior management personnel[199]. - The total remuneration for the chairman and general manager, Lin Hongwei, is 26.65 million yuan[198]. - The total remuneration for the general manager, Yang Zhiling, is 53.48 million yuan[198]. - The total remuneration for the vice general manager, Zhang Chuan Kai, is 88.13 million yuan[198].

Financial Performance - The company's operating revenue for Q1 2025 was ¥79,256,915.65, representing a 44.88% increase compared to ¥54,703,500.18 in the same period last year[4] - The net profit attributable to shareholders was -¥18,414,939.50, a slight increase in loss from -¥16,574,890.90 year-on-year[4] - The increase in operating revenue was primarily driven by the capacity release of the Jiaxing project, leading to higher sales volume[8] - Total revenue for Q1 2025 reached ¥79,256,915.65, a 44.8% increase from ¥54,703,500.18 in Q1 2024[18] - Net loss for Q1 2025 was ¥18,414,939.50, compared to a net loss of ¥16,574,890.90 in Q1 2024, indicating a decline in performance[20] - Operating profit for Q1 2025 was -¥17,918,872.94, slightly worse than -¥16,317,966.73 in Q1 2024[19] Cash Flow and Liquidity - The net cash flow from operating activities was ¥34,214,425.62, showing a 3.99% increase from ¥32,902,787.08 in the previous year[4] - Cash received from sales in Q1 2025 was ¥67,243,064.37, down 20.4% from ¥84,275,755.31 in Q1 2024[22] - The cash inflow from operating activities was $96,855,662.89, compared to $102,849,413.68, showing a decrease of about 6%[23] - Cash and cash equivalents decreased to RMB 141,328,906.84 from RMB 152,211,590.34, indicating a decline of about 7.5%[15] - Cash and cash equivalents at the end of the period totaled $141,328,906.84, down from $94,141,640.85, representing an increase of about 50%[24] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,566,631,061.12, a slight increase of 0.10% from ¥2,563,947,151.17 at the end of the previous year[5] - Total liabilities amounted to ¥1,641,924,855.70, compared to ¥1,620,826,006.25 in the previous period[17] - Non-current liabilities decreased to ¥1,042,230,082.70 from ¥1,135,110,825.51[17] - The company's equity attributable to shareholders was ¥924,706,205.42, down from ¥943,121,144.92[17] Research and Development - Research and development expenses totaled ¥7,467,497.03, which is a 7.33% decrease from ¥8,058,136.82 in the same period last year[4] - The ratio of R&D expenses to operating revenue decreased to 9.42%, down 5.31 percentage points from 14.73% year-on-year[5] - Research and development expenses for Q1 2025 were ¥7,467,497.03, a decrease from ¥8,058,136.82 in Q1 2024[19] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 5,535[10] - The company has not reported any significant changes in shareholder relationships or actions during the reporting period[12] - There were no significant changes in the top 10 shareholders or their participation in margin trading and securities lending activities[12] Other Financial Information - The company recognized government subsidies amounting to ¥1,088,065.33, which are closely related to its normal operations[6] - The financial statements for the quarter ended March 31, 2025, are unaudited[13] - The company has not identified any other important information regarding its operational performance during the reporting period[13] Operating Costs - Total operating costs for Q1 2025 were ¥98,661,338.20, up 37.4% from ¥71,851,557.80 in Q1 2024[18]

Financial Performance - The company's operating revenue for Q1 2025 was CNY 173,957,583.38, representing a 33.93% increase compared to CNY 129,883,899.51 in the same period last year[3] - Net profit attributable to shareholders decreased by 81.31% to CNY 2,742,739.43 from CNY 14,672,292.08 year-on-year[3] - The net profit after excluding non-recurring gains and losses dropped by 97.46% to CNY 353,313.70 from CNY 13,898,883.78 in the previous year[3] - Basic earnings per share decreased by 77.78% to CNY 0.02 from CNY 0.09 in the same period last year[4] - Net profit for Q1 2025 was ¥4,301,154.94, a decrease of 72% compared to ¥15,221,887.95 in Q1 2024[17] - The net profit attributable to shareholders of the parent company for Q1 2025 was ¥2,742,739.43, down 81% from ¥14,672,292.08 in Q1 2024[18] - The total comprehensive income for Q1 2025 was ¥4,394,227.78, significantly lower than ¥15,272,658.76 in Q1 2024[18] Cash Flow - The company reported a net cash flow from operating activities of CNY 40,686,711.92, down 37.70% from CNY 65,312,513.77 year-on-year[3] - Cash flow from operating activities in Q1 2025 was ¥214,086,437.88, compared to ¥208,031,192.36 in Q1 2024, indicating a slight increase[19] - The net cash flow from operating activities was $40,686,711.92, a decrease of 37.8% compared to $65,312,513.77 in the previous period[20] - Total cash inflow from investment activities was $87,669,642.88, slightly up from $87,223,840.87 year-over-year[20] - The net cash flow from investment activities was -$95,674,961.18, worsening from -$41,060,111.99 in the previous period[20] - Cash inflow from financing activities totaled $128,000,000.00, significantly higher than $39,229,533.34 in the prior period[21] - The net cash flow from financing activities was $16,882,888.49, an increase from $9,691,536.10 year-over-year[21] - The total cash and cash equivalents at the end of the period were $471,155,204.80, down from $628,418,213.78 at the beginning of the period[21] - The company paid $84,579,533.34 in debt repayments, compared to $20,450,000.00 in the previous period[21] - The company received $772,416.99 in tax refunds, which is a significant increase from $16,545,941.68 previously[20] - The company’s cash outflow for purchasing goods and services was $103,544,468.74, nearly unchanged from $103,586,307.60 in the prior period[20] - The impact of exchange rate changes on cash and cash equivalents was $1,883,675.27, compared to $811,123.85 in the previous period[21] Assets and Liabilities - The total assets at the end of the reporting period were CNY 2,168,597,997.76, a slight decrease of 0.56% from CNY 2,180,776,351.68 at the end of the previous year[4] - As of March 31, 2025, the company's total assets amounted to approximately ¥2.17 billion, a slight decrease from ¥2.18 billion as of December 31, 2024[11] - The company's cash and cash equivalents decreased to ¥471.79 million from ¥509.42 million, reflecting a decline of about 7.35%[11] - Accounts receivable decreased to ¥238.02 million from ¥270.16 million, representing a reduction of approximately 11.9%[11] - The company's total current liabilities decreased to ¥288.57 million from ¥332.24 million, indicating a decrease of about 13.14%[12] - Long-term equity investments remained relatively stable at ¥53.14 million compared to ¥53.31 million, showing a minor decrease of 0.32%[12] - The company's fixed assets decreased to ¥678.34 million from ¥691.43 million, a decline of approximately 1.89%[12] - The company's inventory remained stable at approximately ¥197.74 million, showing no significant change from the previous period[11] - The company reported a total current asset of approximately ¥1.10 billion, a slight decrease from ¥1.12 billion, reflecting a decline of about 1.6%[11] - The company's total non-current assets increased to approximately ¥1.07 billion from ¥1.06 billion, indicating a growth of about 0.68%[12] - Total liabilities decreased to ¥877,415,349.33 in Q1 2025 from ¥887,755,543.06 in Q1 2024[16] - Total equity attributable to shareholders of the parent company was ¥1,273,996,414.07, slightly down from ¥1,277,691,164.39 in Q1 2024[16] Research and Development - R&D investment totaled CNY 23,651,737.23, an increase of 10.43% from CNY 21,418,316.46, accounting for 13.60% of operating revenue[4] - Research and development expenses for Q1 2025 were ¥23,651,737.23, an increase from ¥21,418,316.46 in Q1 2024[17] Management and Operations - The company anticipates that the economic benefits from new business demands will gradually restore profitability as capacity utilization improves[4] - The increase in management expenses by CNY 3,150,600 was attributed to the underutilization of new capacities in Hunan and Vietnam factories[7] - The total number of ordinary shareholders at the end of the reporting period was 6,514[8] - The company has not reported any significant changes in shareholder structure or major financing activities during the reporting period[10]

Financial Performance - The company's operating revenue for Q1 2025 reached ¥554,270,119.55, representing a 60.52% increase compared to ¥345,288,588.23 in the same period last year[4] - Net profit attributable to shareholders was ¥70,568,105.32, a significant increase of 116.96% from ¥32,525,834.62 year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥66,574,118.95, reflecting a 177.92% increase compared to ¥23,954,687.67 in the previous year[4] - Basic earnings per share rose to ¥0.17, up 112.50% from ¥0.08 in the same quarter last year[4] - Total operating revenue for Q1 2025 reached ¥554,270,119.55, a significant increase of 60.4% compared to ¥345,288,588.23 in Q1 2024[16] - Operating costs for Q1 2025 were ¥479,907,755.43, up 50.7% from ¥318,555,826.08 in Q1 2024[16] - Net profit for Q1 2025 was ¥70,568,105.32, representing a 116.7% increase from ¥32,525,834.62 in Q1 2024[17] - Basic and diluted earnings per share for Q1 2025 were both ¥0.17, compared to ¥0.08 in Q1 2024[18] - The company reported a total comprehensive income of ¥71,577,356.98 for Q1 2025, compared to ¥34,638,933.50 in Q1 2024[18] Research and Development - The total R&D investment amounted to ¥47,336,306.48, which is a 23.06% increase from ¥38,466,345.99 in the previous year[5] - Research and development expenses for Q1 2025 were ¥47,336,306.48, up from ¥38,466,345.99 in Q1 2024, indicating a focus on innovation[16] - The proportion of R&D investment to operating revenue decreased to 8.54%, down from 11.14% year-on-year[5] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,666,031,546.71, a 3.56% increase from ¥2,574,288,758.72 at the end of the previous year[5] - Current assets totaled CNY 2,529,816,486.65, up from CNY 2,373,320,481.36 in the previous period[13] - Cash and cash equivalents were reported at CNY 1,730,573,283.00, slightly down from CNY 1,757,374,244.05[12] - Accounts receivable decreased to CNY 226,019,967.00 from CNY 244,221,857.14[13] - Inventory increased significantly to CNY 335,017,892.57 from CNY 244,490,892.96[13] - Total liabilities rose to CNY 410,728,053.74 compared to CNY 394,140,140.39 in the previous period[14] - The company reported a decrease in accounts payable to CNY 229,546,582.61 from CNY 202,417,844.80[14] - Non-current assets totaled CNY 136,215,060.06, down from CNY 200,968,277.36[13] - The company's total equity remains unspecified in the provided data[14] Cash Flow - The net cash flow from operating activities was negative at -¥23,474,455.83, an improvement from -¥38,743,973.36 in the previous year[4] - Cash inflow from operating activities in Q1 2025 totaled ¥633,421,910.18, an increase from ¥365,005,854.28 in Q1 2024[18] - The net cash flow from operating activities was -$23.47 million, an improvement from -$38.74 million in the previous period[19] - Cash inflow from investment activities totaled $184.81 million, significantly up from $30 million year-over-year[19] - The net cash flow from investment activities was $63.09 million, compared to a negative $18.11 million in the prior period[19] - Cash outflow from financing activities was $889,869.67, a decrease from $49.30 million in the previous period[19] - The net increase in cash and cash equivalents was $41.94 million, contrasting with a decrease of $104.75 million in the prior period[19] - The ending balance of cash and cash equivalents was $250.51 million, compared to $268.73 million at the end of the previous period[19] Shareholder and Financing Activities - The company has not reported any significant changes in shareholder structure or financing activities during the reporting period[11] - The company plans to implement new accounting standards starting in 2025, which may affect financial reporting[19] Profitability - The weighted average return on net assets was 3.18%, up from 1.65% in the same period last year, indicating improved profitability[4] - The company's retained earnings increased to ¥871,642,738.64, compared to ¥801,074,633.32 in the previous year[15] - The total equity attributable to shareholders increased to ¥2,255,303,492.97, compared to ¥2,180,148,618.33 in the previous year[15]

Financial Performance - The company's revenue for Q1 2025 reached ¥282,885,275.77, representing a 63.42% increase compared to ¥173,108,475.50 in the same period last year[4]. - Net profit attributable to shareholders was ¥7,805,691.91, an increase of 81.78% from ¥4,294,058.13 year-on-year[4]. - The net profit after deducting non-recurring gains and losses was ¥754,705.54, showing a significant increase of 144.13% compared to ¥309,146.43 in the previous year[4]. - The company's basic and diluted earnings per share both increased by 50.00%, reaching ¥0.06 per share[4]. - Total operating revenue for Q1 2025 reached ¥282,885,275.77, a significant increase of 63.5% compared to ¥173,108,475.50 in Q1 2024[18]. - Operating profit for Q1 2025 was ¥2,856,413.79, up from ¥1,793,073.33 in Q1 2024, reflecting a growth of 59.3%[19]. - Net profit for Q1 2025 was ¥5,410,411.52, compared to ¥4,294,058.13 in Q1 2024, representing an increase of 26.0%[19]. - Basic and diluted earnings per share for Q1 2025 were both ¥0.06, an increase from ¥0.04 in Q1 2024[20]. - The total comprehensive income for Q1 2025 was ¥5,409,870.09, compared to ¥4,294,109.67 in Q1 2024, reflecting a growth of 25.9%[20]. Cash Flow and Investments - The net cash flow from operating activities was negative at -¥87,146,532.15, compared to -¥13,830,773.47 in the same period last year, indicating increased cash outflows[4][8]. - Cash flow from operating activities for Q1 2025 was negative at -¥87,146,532.15, worsening from -¥13,830,773.47 in Q1 2024[21]. - Cash flow from investing activities showed a net outflow of -¥955,336,081.69 in Q1 2025, compared to -¥569,792,701.52 in Q1 2024, indicating increased investment activity[21]. - The company reported a cash and cash equivalents balance of ¥1,043,125,963.25 at the end of Q1 2025, down from ¥1,661,541,583.87 at the end of Q1 2024[21]. Assets and Liabilities - Total assets at the end of the reporting period were ¥3,110,952,021.03, a slight increase of 0.36% from ¥3,099,883,346.78 at the end of the previous year[5]. - The company's current assets totaled RMB 2,768,481,817.81, showing a decrease from RMB 2,801,426,577.49 in the previous period[14]. - Cash and cash equivalents decreased significantly from RMB 2,084,185,195.71 to RMB 1,043,125,963.25, representing a decline of approximately 50%[13]. - The company's inventory increased from RMB 360,602,241.41 to RMB 420,984,536.61, reflecting a growth of about 16.7%[14]. - Short-term borrowings rose from RMB 4,760,271.90 to RMB 16,750,271.90, indicating an increase of approximately 251%[15]. - Total liabilities increased from RMB 200,139,616.66 to RMB 209,158,780.96, marking a rise of about 4.5%[15]. - The equity attributable to shareholders increased slightly from RMB 2,899,743,730.12 to RMB 2,907,548,880.60, showing a growth of approximately 0.3%[16]. - The company reported a decrease in accounts payable from RMB 150,994,482.48 to RMB 147,971,768.92, a decline of about 2%[15]. - The company's long-term equity investments increased from RMB 155,292,109.13 to RMB 178,380,392.35, reflecting a growth of approximately 14.9%[14]. Research and Development - Research and development expenses totaled ¥19,916,625.75, accounting for 7.04% of revenue, down from 11.61% in the previous year, a decrease of 4.57 percentage points[5]. - Research and development expenses for Q1 2025 were ¥19,916,625.75, slightly down from ¥20,102,415.25 in Q1 2024, indicating a decrease of 0.9%[18]. Company Strategy and Market Position - The company attributed revenue growth to optimizing product mix strategies, expanding production capacity, and increasing demand in key application areas such as 5G base station power supplies and electric vehicle charging[7]. - The company has not disclosed any new product developments or market expansion strategies during this reporting period[12]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 11,820[10]. - The weighted average return on equity increased by 0.12 percentage points to 0.27%[4]. Foreign Exchange Impact - The company experienced a foreign exchange loss of -¥541.43 in Q1 2025, contrasting with a gain of ¥51.54 in Q1 2024[21].

Financial Performance - The company's revenue for Q1 2025 was ¥909,945,198.53, representing a year-on-year increase of 9.61% compared to ¥830,133,907.19 in the same period last year[4] - The net profit attributable to shareholders was a loss of ¥122,238,253.41, slightly improved from a loss of ¥125,285,669.54 in the previous year[4] - Total operating revenue for Q1 2025 reached ¥909,945,198.53, an increase of 9.6% compared to ¥830,133,907.19 in Q1 2024[17] - Net profit for Q1 2025 was a loss of ¥122,238,253.41, slightly improved from a loss of ¥125,285,669.54 in Q1 2024[18] - The company reported a total comprehensive loss of ¥125,639,748.00 for Q1 2025, compared to a loss of ¥132,351,736.68 in Q1 2024[19] Research and Development - Research and development (R&D) expenses totaled ¥357,257,685.32, an increase of 12.88% from ¥316,480,241.79, accounting for 39.26% of total revenue, up from 38.12%[5] - Research and development expenses for Q1 2025 amounted to ¥357,257,685.32, an increase of 12.9% from ¥316,480,241.79 in Q1 2024[18] Cash Flow - The company reported a net cash flow from operating activities of -¥183,222,888.41, an improvement from -¥228,518,251.87 in the previous year[4] - Cash inflow from operating activities in Q1 2025 was ¥852,991,323.38, compared to ¥644,054,320.13 in Q1 2024, reflecting a growth of 32.4%[21] - The net cash flow from operating activities was -$183.22 million, an improvement from -$228.52 million in the previous period[22] - The net increase in cash and cash equivalents was $390.40 million, contrasting with a decrease of $110.21 million in the previous period[22] - The ending balance of cash and cash equivalents was $3.01 billion, up from $2.44 billion year-over-year[22] Assets and Liabilities - The total assets at the end of the reporting period were ¥6,405,918,272.81, a decrease of 2.00% from ¥6,536,868,670.00 at the end of the previous year[5] - Total current assets as of March 31, 2025, amount to ¥5,374,727,831.06, a decrease from ¥5,473,216,050.76 as of December 31, 2024[13] - Total liabilities as of March 31, 2025, are ¥737,727,135.46, slightly up from ¥736,294,799.95[14] - The total liabilities as of the latest reporting period were ¥799,307,423.37, a decrease from ¥855,090,183.65[15] - The company’s non-current assets total ¥1,031,190,441.75, down from ¥1,063,652,619.24[14] Shareholder Information - Total number of common shareholders at the end of the reporting period is 19,780[10] - The largest shareholder, Alibaba (China) Network Technology Co., Ltd., holds 64,557,440 shares, accounting for 15.43% of total shares[10] - The company has a share repurchase account holding 13,358,771 shares, representing 3.19% of total shares as of March 31, 2025[11] Earnings Per Share - The basic earnings per share were -¥0.30, slightly improved from -¥0.31 in the same period last year[5] - Basic and diluted earnings per share for Q1 2025 were both -¥0.30, compared to -¥0.31 in Q1 2024[19] Other Financial Metrics - The weighted average return on equity was -2.17%, a decrease of 0.18 percentage points from -1.99%[5] - The company experienced an increase in gross profit margin, with total gross profit rising by ¥42,754,300, a growth rate of 21.70%[7] - Non-recurring gains and losses amounted to ¥59,817,380.47, primarily from government subsidies and other non-operating income[6] - Deferred income as of the latest reporting period was ¥30,861,768.06, down from ¥87,843,100.27[15] Accounting Standards - The company plans to implement new accounting standards starting in 2025[23]